Categories: Entertainment

Authors, Publishers, and Copyright Owners May Benefit from a $1.5 Billion Class Action Settlement

SEATTLE, Oct. 7, 2025 /PRNewswire/ —

- Advertisement -

JND Legal Administration

- Advertisement -

A proposed class action settlement was reached in the lawsuit, Bartz v. Anthropic PBC, which claimed that Anthropic infringed copyrights by downloading allegedly pirated datasets containing copyrighted books. Anthropic denies the allegations.

- Advertisement -

Authors, publishers, and copyright owners may be Class Members and benefit from the Settlement if they own the copyright of a work included in the LibGen or PiLiMi datasets downloaded by Anthropic.

- Advertisement -

More details and a searchable database of all books included in the settlement are available at www.AnthropicCopyrightSettlement.com.

- Advertisement -

Class Members have the following options:

- Advertisement -
  1. File a Claim by March 23, 2026 to receive payment from the $1.5 billion Settlement Fund.
  2. Exclude Yourself and All Rightsholders (or Opt Out) by January 7, 2026 to give up all rights to receive payment from this Settlement and have the option to bring your own separate lawsuit against Anthropic for the claims this Settlement resolves.
  3. Object by January 7, 2026 if you disagree with the Settlement and want to remain a Class Member.
  4. Do nothing. You may or may not receive money from the Settlement, and you are not guaranteed a payment unless you submit a valid Claim Form.

The Court scheduled a hearing for April 23, 2026, at 12:00 PT at the San Francisco Federal Courthouse, 450 Golden Gate Ave., Courtroom 12 – 19th Floor, to consider whether to approve the Settlement. The Court will also consider Class Counsel’s request for attorneys’ fees of up to 25% of the Settlement Fund, reimbursement for other costs and expenses, and service payments of up to $50,000 to each Class Representative, as well as any objections.

- Advertisement -

Contact Information:

- Advertisement -

Write:


Bartz v Anthropic

c/o JND Legal Administration

P.O. Box 91204

Seattle, WA 98111

Complete copies of the pleadings, orders and other publicly filed documents in the lawsuit may also be accessed for a fee through the Court’s Public Access to Court Electronic Records (PACER) system at https://ecf.cand.uscourts.gov.

- Advertisement -

PLEASE DO NOT CONTACT THE COURT REGARDING THIS NOTICE.

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/authors-publishers-and-copyright-owners-may-benefit-from-a-1-5-billion-class-action-settlement-302576041.html

- Advertisement -
PRNW Agency

Recent Posts

Crypto News: AlphaPepe Presale Records Surge in Whale Accumulation As Bitcoin Price Prediction Eyes $180,000

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…

4 hours ago

Crypto Market News: AlphaPepe Finalizes Tier-1 Exchange Shortlist as XRP Price Prediction Targets $5.00

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…

4 hours ago

Qoder Version 1.0 Released: Full Automation of Code Generation, Verification & Delivery

SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…

4 hours ago

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…

4 hours ago

ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026

– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract…

4 hours ago

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast…

4 hours ago